000283151 001__ 283151
000283151 005__ 20260108150726.0
000283151 0247_ $$2doi$$a10.1212/NXI.0000000000200531
000283151 0247_ $$2pmid$$apmid:41499724
000283151 037__ $$aDZNE-2026-00047
000283151 041__ $$aEnglish
000283151 082__ $$a610
000283151 1001_ $$00009-0000-4271-4763$$aPakeerathan, Thivya$$b0
000283151 245__ $$aOCT-Based Differentiation of First Acute Optic Neuritis: An International Study of 111 Patients With NMOSD and MOGAD.
000283151 260__ $$aPhiladelphia, Pa.$$bWolters Kluwer$$c2026
000283151 3367_ $$2DRIVER$$aarticle
000283151 3367_ $$2DataCite$$aOutput Types/Journal article
000283151 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1767881151_14471
000283151 3367_ $$2BibTeX$$aARTICLE
000283151 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000283151 3367_ $$00$$2EndNote$$aJournal Article
000283151 520__ $$aSevere optic neuritis (ON) is a common clinical manifestation in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and neuromyelitis optica spectrum disorder (NMOSD). Given distinct prognoses and often the necessity of early plasma exchange in NMOSD, prompt differentiation is crucial. In this study, we investigated the utility of optical coherence tomography (OCT) in differentiating between first acute NMOSD-ON and MOGAD-associated optic neuritis (MOGAD-ON), as well as specific factors associated with disc edema.In this retrospective multicenter study, 111 adult patients with MOGAD or aquaporin-4 antibody-positive NMOSD who experienced a first ON and underwent OCT within 2 weeks of symptom onset were included from 14 centers across 8 countries. Peripapillary retinal nerve fiber layer (pRNFL) thickness in µm was analyzed, including the average of both eyes in cases of bilateral manifestation.Eighty-three patients with MOGAD (51 women; 124 ON eyes; bilateral ON 48.2%) and 28 with NMOSD (24 women; 36 ON eyes; bilateral ON 21.4%) were enrolled. A significant increase in pRNFL thickness (>2SD), suggestive of disc edema, was observed in 73.4% of MOGAD-ON eyes and 11.1% of NMOSD-ON eyes (p < 0.001). The pRNFL thickness cutoff of 117.5 µm provided 92.9% specificity and 71.1% sensitivity in distinguishing between MOGAD-ON and NMOSD-ON (area under the curve = 0.838). There was no association between pRNFL thickening and MOG-IgG titer (high vs low), body mass index, or the delay between ON onset and OCT. Simultaneous bilateral MOGAD-ON was associated with significantly more pronounced pRNFL thickening.Acute-stage OCT contributes to the rapid and accurate differentiation between MOGAD-ON and NMOSD-ON prior to antibody confirmation, which can be critical for timely therapeutic decisions.
000283151 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000283151 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000283151 650_7 $$2NLM Chemicals$$aMyelin-Oligodendrocyte Glycoprotein
000283151 650_7 $$2NLM Chemicals$$aAquaporin 4
000283151 650_7 $$2NLM Chemicals$$aAutoantibodies
000283151 650_2 $$2MeSH$$aHumans
000283151 650_2 $$2MeSH$$aTomography, Optical Coherence: methods
000283151 650_2 $$2MeSH$$aFemale
000283151 650_2 $$2MeSH$$aOptic Neuritis: diagnostic imaging
000283151 650_2 $$2MeSH$$aOptic Neuritis: diagnosis
000283151 650_2 $$2MeSH$$aMale
000283151 650_2 $$2MeSH$$aAdult
000283151 650_2 $$2MeSH$$aNeuromyelitis Optica: diagnosis
000283151 650_2 $$2MeSH$$aNeuromyelitis Optica: diagnostic imaging
000283151 650_2 $$2MeSH$$aMiddle Aged
000283151 650_2 $$2MeSH$$aRetrospective Studies
000283151 650_2 $$2MeSH$$aDiagnosis, Differential
000283151 650_2 $$2MeSH$$aMyelin-Oligodendrocyte Glycoprotein: immunology
000283151 650_2 $$2MeSH$$aYoung Adult
000283151 650_2 $$2MeSH$$aAquaporin 4: immunology
000283151 650_2 $$2MeSH$$aAged
000283151 650_2 $$2MeSH$$aAutoantibodies
000283151 650_2 $$2MeSH$$aMyelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
000283151 7001_ $$00009-0001-2618-4894$$aDavis, James$$b1
000283151 7001_ $$00000-0002-8676-4292$$aHenderson, Amanda D$$b2
000283151 7001_ $$00000-0002-8812-1637$$aSotirchos, Elias S$$b3
000283151 7001_ $$00009-0004-4350-1910$$aSaid, Yana$$b4
000283151 7001_ $$00000-0002-4386-1340$$aHavla, Joachim$$b5
000283151 7001_ $$00000-0003-3618-8407$$aRingelstein, Marius$$b6
000283151 7001_ $$00000-0002-2020-9210$$aAktas, Orhan$$b7
000283151 7001_ $$aWeise, Margit$$b8
000283151 7001_ $$00000-0002-6655-5557$$aGernert, Jonathan A$$b9
000283151 7001_ $$00000-0002-1851-6967$$aKornek, Barbara$$b10
000283151 7001_ $$00000-0002-0825-0851$$aBsteh, Gabriel$$b11
000283151 7001_ $$00000-0001-5209-6647$$aRommer, Paulus S$$b12
000283151 7001_ $$00000-0002-4146-5870$$aKrajnc, Nik$$b13
000283151 7001_ $$0P:(DE-2719)9003515$$aPröbstel, Anne-Katrin$$b14
000283151 7001_ $$00000-0002-0367-1008$$aPapadopoulou, Athina$$b15
000283151 7001_ $$00000-0001-5236-8323$$aKulsvehagen, Laila$$b16
000283151 7001_ $$00009-0001-4129-1276$$aPretzsch, Roxanne$$b17
000283151 7001_ $$00009-0004-7755-4447$$aSchoenholzer, Kean$$b18
000283151 7001_ $$00000-0002-5840-6172$$aPadungkiatsagul, Tanyatuth$$b19
000283151 7001_ $$00000-0003-4373-447X$$aMoss, Heather E$$b20
000283151 7001_ $$00009-0002-1013-7417$$aVillarreal Navarro, Sylvia E$$b21
000283151 7001_ $$00000-0001-5125-4594$$aHerwerth, Marina$$b22
000283151 7001_ $$00009-0003-5249-4567$$aGraure, Madalina$$b23
000283151 7001_ $$00000-0002-9362-3156$$aKana, Veronika$$b24
000283151 7001_ $$00000-0001-7715-6706$$aStiebel-Kalish, Hadas$$b25
000283151 7001_ $$aZlatkin, Rita$$b26
000283151 7001_ $$00000-0002-9015-4542$$aArnold, Anthony C$$b27
000283151 7001_ $$00000-0001-8819-3756$$aBonelli, Laura$$b28
000283151 7001_ $$00000-0003-2565-2833$$aStellmann, Jan-Patrick$$b29
000283151 7001_ $$00000-0003-3662-3800$$aStolowy, Natacha$$b30
000283151 7001_ $$00000-0003-3669-7244$$aSchwake, Carolin$$b31
000283151 7001_ $$00000-0002-9232-201X$$aSchneider-Gold, Christiane$$b32
000283151 7001_ $$00000-0001-7509-5268$$aKümpfel, Tania$$b33
000283151 7001_ $$00000-0001-7987-658X$$aAlbrecht, Philipp$$b34
000283151 7001_ $$00000-0002-1698-0520$$aRattanathamsakul, Natthapon$$b35
000283151 7001_ $$00000-0002-6140-5584$$aPittock, Sean J$$b36
000283151 7001_ $$00000-0002-6661-2910$$aFlanagan, Eoin P$$b37
000283151 7001_ $$00000-0001-5248-456X$$aCarta, Sara$$b38
000283151 7001_ $$00000-0002-7806-3103$$aMariotto, Sara$$b39
000283151 7001_ $$00000-0002-7223-3052$$aGold, Ralf$$b40
000283151 7001_ $$00000-0003-3644-7528$$aChen, John J$$b41
000283151 7001_ $$00009-0007-9491-2180$$aAyzenberg, Ilya$$b42
000283151 773__ $$0PERI:(DE-600)2767740-0$$a10.1212/NXI.0000000000200531$$gVol. 13, no. 2, p. e200531$$n2$$pe200531$$tNeurology: Neuroimmunology & Neuroinflammation ; official journal of the American Academy of Neurology$$v13$$x2332-7812$$y2026
000283151 8564_ $$uhttps://pub.dzne.de/record/283151/files/DZNE-2026-00047.pdf$$yRestricted
000283151 8564_ $$uhttps://pub.dzne.de/record/283151/files/DZNE-2026-00047.pdf?subformat=pdfa$$xpdfa$$yRestricted
000283151 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003515$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b14$$kDZNE
000283151 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000283151 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROL-NEUROIMMUNOL : 2022$$d2024-12-27
000283151 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-27
000283151 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-27
000283151 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-02-13T18:57:06Z
000283151 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-02-13T18:57:06Z
000283151 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2021-02-13T18:57:06Z
000283151 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-27
000283151 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-27
000283151 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-27
000283151 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-27
000283151 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-27
000283151 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEUROL-NEUROIMMUNOL : 2022$$d2024-12-27
000283151 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-27
000283151 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-27
000283151 9201_ $$0I:(DE-2719)1013045$$kAG Pröbstel$$lClinical Neurology and Neuroimmunology$$x0
000283151 980__ $$ajournal
000283151 980__ $$aEDITORS
000283151 980__ $$aVDBINPRINT
000283151 980__ $$aI:(DE-2719)1013045
000283151 980__ $$aUNRESTRICTED